Delayed Tolerance Through Mixed Chimerism
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
- Status
- UNKNOWN
- Phase
- PHASE2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
- Status
- RECRUITING
- Phase
- PHASE2
A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
- Status
- RECRUITING
- Phase
- PHASE3
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immune Thrombocytopenia Management in Adults
- Status
- UNKNOWN
- Phase
- PHASE4
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
- Status
- RECRUITING
- Phase
- PHASE3
Anti-CD20 Antibodies for Treatment of SLE-PAH
- Status
- RECRUITING
- Phase
- PHASE4
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
- Status
- UNKNOWN
- Phase
- NA
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- Status
- RECRUITING
- Phase
- NA
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
- Status
- RECRUITING
- Phase
- PHASE2